FOLD250516P4000
- 0.05
- 0.000.00%
Amicus Therapeutics Newsroom
Amicus Therapeutics Is Maintained at Buy by UBS
UBS Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Raises Target Price to $22
Wells Fargo Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $13
Amicus Therapeutics Analyst Ratings
Needham Maintains Amicus Therapeutics(FOLD.US) With Hold Rating
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
BofA Securities Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $14
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Morgan Stanley Initiates Amicus Therapeutics(FOLD.US) With Hold Rating, Announces Target Price $12
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $16
Morgan Stanley Maintains Amicus Therapeutics(FOLD.US) With Hold Rating, Maintains Target Price $12
Amicus Therapeutics Is Maintained at Overweight by Wells Fargo
A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $12 to $20
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics: Promising Growth and Strong Financial Guidance Justify Buy Rating
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Morgan Stanley Maintains Amicus Therapeutics(FOLD.US) With Hold Rating, Maintains Target Price $12
Cantor Fitzgerald Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $21
Amicus Therapeutics Analyst Ratings